Introduction: Venetoclax (VEN) combined with Azacytidine (AZA) or Low dose cytarabine (LDAC) is the standard of care for patients (pts) with newly diagnosed acute myeloid leukemia (AML) aged ≥ 75 yrs or not candidates to intensive treatment. However, some pts,...
Introduction: Liposomal cytarabine and daunorubicin (CPX-351) is an approved therapy for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, for which it showed improved response rate and overall survival (OS) up to 5 years compared with...
For older AML populations ineligible for intensive chemotherapy and allogeneic stem cell transplantation, combining the BH3 mimetic venetoclax (VEN) with hypomethylating agents has emerged as first-line therapy. Despite early responses, resistance to VEN, marked by...
Among the spectrum of mutations driving malignancy, mutation in the TP53 gene is perhaps the most important event leading to therapy resistance. Only ~25% of patients with TP53-mutated acute myeloid leukemia (AML) respond to standard induction therapy, with dismal...
Imetelstat is a first-in-class telomerase inhibitor with recent FDA approval for the treatment of myelodysplastic syndromes (Platzbecker et al. Lancet 2024). We have previously shown that imetelstat is effective in randomized, preclinical trials in Acute Myeloid...
Recent Comments